GSK-3 inhibition potentiates the synaptogenic and antidepressant-like effects of subthreshold doses of ketamine - Wikidata - wikimedia - TriplyDB

GSK-3 inhibition potentiates the synaptogenic and antidepressant-like effects of subthreshold doses of ketamine

GSK-3 inhibition potentiates the synaptogenic and antidepressant-like effects of subthreshold doses of ketamine

http://www.wikidata.org/entity/Q37172762

about

Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants Neuroplasticity and the next wave of antidepressant strategies Potential of Glutamate-Based Drug Discovery for Next Generation Antidepressants A Review of Biomarkers in Mood and Psychotic Disorders: A Dissection of Clinical vs. Preclinical Correlates Antidepressant mechanism of ketamine: perspective from preclinical studies Antidepressant actions of ketamine: from molecular mechanisms to clinical practice Optogenetic stimulation of infralimbic PFC reproduces ketamine's rapid and sustained antidepressant actions.Glycogen synthase kinase-3β inhibition in the medial prefrontal cortex mediates paradoxical amphetamine action in a mouse model of ADHD.The mood stabilizer lithium potentiates the antidepressant-like effects and ameliorates oxidative stress induced by acute ketamine in a mouse model of stress Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder DIXDC1 contributes to psychiatric susceptibility by regulating dendritic spine and glutamatergic synapse density via GSK3 and Wnt/β-catenin signaling.Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants.NMDA Receptors Regulate the Structural Plasticity of Spines and Axonal Boutons in Hippocampal Interneurons.Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds.Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics Circadian dysregulation of clock genes: clues to rapid treatments in major depressive disorder.Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review.Pathophysiology of depression and innovative treatments: remodeling glutamatergic synaptic connections.GluN2B-containing NMDA receptors regulate depression-like behavior and are critical for the rapid antidepressant actions of ketamine Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression.NMDA receptor subunits and associated signaling molecules mediating antidepressant-related effects of NMDA-GluN2B antagonism.Lithium and Valproate Levels Do Not Correlate with Ketamine's Antidepressant Efficacy in Treatment-Resistant Bipolar Depression Spine synapse remodeling in the pathophysiology and treatment of depression.Clozapine counteracts a ketamine-induced depression of hippocampal-prefrontal neuroplasticity and alters signaling pathway phosphorylation Neuronal correlates of depression.GABAergic control of depression-related brain states Longitudinal Effects of Ketamine on Dendritic Architecture In Vivo in the Mouse Medial Frontal Cortex Group II mGlu receptor antagonist LY341495 enhances the antidepressant-like effects of ketamine in the forced swim test in rats Molecular and Cellular Mechanisms of Rapid-Acting Antidepressants Ketamine and Scopolamine Modulation of the activity of N-methyl-d-aspartate receptors as a novel treatment option for depression: current clinical evidence and therapeutic potential of rapastinel (GLYX-13).Mechanisms underlying the neuroprotective effect of brain reserve against late life depression.Neurobiology of stress, depression, and rapid acting antidepressants: remodeling synaptic connections.Ameliorating treatment-refractory depression with intranasal ketamine: potential NMDA receptor actions in the pain circuitry representing mental anguish.A Circadian Genomic Signature Common to Ketamine and Sleep Deprivation in the Anterior Cingulate Cortex.New perspectives on the involvement of mTOR in depression as well as in the action of antidepressant drugs.Targeting glutamate signalling in depression: progress and prospects.Treating the Synapse in Major Psychiatric Disorders: The Role of Postsynaptic Density Network in Dopamine-Glutamate Interplay and Psychopharmacologic Drugs Molecular Actions PPARgamma agonists rescue increased phosphorylation of FGF14 at S226 in the Tg2576 mouse model of Alzheimer's disease.Ketamine: A Review of Clinical Pharmacokinetics and Pharmacodynamics in Anesthesia and Pain Therapy.KETAMINE'S MECHANISM OF ACTION: A PATH TO RAPID-ACTING ANTIDEPRESSANTS.

P2860

Q21129276-DF0F3E0D-896A-4842-A3DE-693A943BC78A Q21129480-50025BBC-B055-4274-AD7F-FD450B9B862A Q26782274-C67E85E8-D612-40A5-AE3D-8ECD395DAAC5 Q26786354-218B04F6-BC1E-47F3-8ACC-5C5A39F1B340 Q26800231-D94BF315-E98E-409B-90F3-909D4F671C56 Q26995879-D2245954-0BF4-4D33-B442-A7CE1A729A94 Q27328579-4BD1C021-0FFF-465C-95BC-429ECDA1667E Q30414710-A317F529-4245-47B0-823A-6C9D2A68AD47 Q30651146-56C7E735-1489-417E-9667-BAE82EA1DA60 Q30711088-A910499B-89C5-4266-B913-C6B6A13FA20F Q33574930-A30E8E4E-F4F9-4B7D-98B0-E2A4D326B1DD Q33604879-BEC4B17C-136F-4ADA-A318-B782C4BBFBDD Q33785739-7E1AAEBD-CB46-4728-9989-5FC144098CE8 Q33874459-2B7EB182-1726-494C-85C0-7E83C127AC0E Q34444632-FE377FA0-AB37-4C3C-BDDE-84A637460849 Q34445122-AEC88F0B-26EB-4DCD-BE19-BC62B37824B7 Q34475595-B6D98AAF-8782-4A61-A8B3-9C815A5CAFC8 Q34661281-31B85298-B5F2-4748-89A6-DF6DEDB6E82E Q34729421-2645B4C2-159F-4B7E-B475-22AE486FF16E Q35150163-5BA75384-FA68-4261-A7B3-4252CABB74E3 Q35586357-403BCD83-4928-4B1A-8568-4E67FFCB6740 Q35763203-7C8F41DF-72E1-49C4-9670-C1891610211D Q35836787-EEBACE16-5ABE-4FEE-9D8E-D57C3CC90CD9 Q36363351-F4CEF146-8943-4D7D-B87A-22AF21DC8E5E Q36451816-4C5E6C51-73A1-4371-961E-F73D5706C9C8 Q36668325-8CC6D934-9BDA-4A44-B3AE-FEA95321FE7D Q36760919-D76F651F-1872-49FF-BFCE-BC290EA48DFE Q37067121-00BAEE34-5BDB-439E-96DF-B4A7EDB0C279 Q37668009-C77A8693-B373-4349-9109-2B879D5F9FC2 Q37741989-498A9BB5-BABB-447F-9418-F88D87786583 Q38175828-3BABC7B6-0F21-4AF3-B033-740EE08645F5 Q38194996-DC286E3F-9631-4FDD-879D-98E874B583D1 Q38331726-ECD9AE2E-D1F5-45B2-9A9C-B9C6B02B5294 Q38434930-817F0CE5-BA26-4873-A5E9-7EBC37E715BA Q38650284-C4759D00-650F-4E46-92B5-FA8175B9B0BC Q38743867-D6DBE8C8-E89F-4753-BAF0-E2BC9BCEBA96 Q38770806-68AEE980-C28A-4072-BD81-A27943FC7AAA Q38776236-E8BAEADA-C3A6-4B11-8876-807C674CCE2D Q38793772-10A9973B-7D8F-4228-86B9-216FD681B089 Q38803371-446E1291-509B-416E-8716-D54713EC4A37

P2860

GSK-3 inhibition potentiates the synaptogenic and antidepressant-like effects of subthreshold doses of ketamine

http://www.wikidata.org/entity/Q37172762

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 17 May 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

GSK-3 inhibition potentiates t ...... subthreshold doses of ketamine

@en

GSK-3 inhibition potentiates t ...... ubthreshold doses of ketamine.

@nl

type

label

GSK-3 inhibition potentiates t ...... subthreshold doses of ketamine

@en

GSK-3 inhibition potentiates t ...... ubthreshold doses of ketamine.

@nl

prefLabel

GSK-3 inhibition potentiates t ...... subthreshold doses of ketamine

@en

GSK-3 inhibition potentiates t ...... ubthreshold doses of ketamine.

@nl

P1433

Q37172762-5BEF2E62-F569-466D-BB82-D61DA16AE053

P1476

Q37172762-CDC407CD-C2D2-4385-8F1A-385E765EF5E4

P2093

Q37172762-3C3FE298-51FF-44E3-A22C-26D63E69E8CE

Q37172762-67EBED58-3EDC-4849-86F0-A6E9142D61BC

Q37172762-7C2C46AF-FBFF-46ED-82A6-EE26603F52AE

Q37172762-8530FB64-A8F8-4181-AFB9-C71132798BFA

Q37172762-9EAC2F27-2D2D-4233-99D0-66392A2D1FE7

Q37172762-B7B19E93-34A1-47F7-A7C2-D6559C459579

P2860

Q37172762-03B2E2C7-5187-4244-BE0F-633FD6622968

Q37172762-08807818-5AB8-40BE-A317-B33775BD8F76

Q37172762-095F61FB-1C32-42A4-82C5-65F5D00BA020

Q37172762-1085B5C3-3C35-4804-AD06-CBCF7CA2EEEC

Q37172762-15B4CD15-F9E8-41FB-9BD0-5D02DD3204FC

Q37172762-19296279-DCD5-4066-83E3-A444F6251827

Q37172762-1FB2171C-2F59-46FD-8E99-074C01CC5980

Q37172762-252E75F7-2CCC-4F84-A851-013B9B3CC718

Q37172762-3ABE02B9-29D1-4026-8825-DEAFFA478D0C

Q37172762-42449A9F-73F6-4F5E-83C6-40964352A5C1

P2888

Q37172762-D28892ED-8AF6-438C-A306-DC9A951553FF

P304

Q37172762-D5AA7C2A-17B9-4502-9046-BBBE7BD0842F

P31

Q37172762-C265F8B4-CB1B-4F2B-A048-C8388DC83E6A

P356

Q37172762-22EB1370-52AC-410B-94EF-B88160B0705D

P407

Q37172762-12E99197-66AF-4011-AEB4-F221855D2061

P433

Q37172762-5FE25269-60E1-47D2-AF07-A52E5E5BEEF4

P478

Q37172762-7882828D-41D2-4193-A776-B48843F17B7D

P577

Q37172762-09BBEAC8-E589-4ADB-96D0-2F6498F84348

P5875

Q37172762-E59F3533-4981-4F50-A80E-5C91CAB05FA4

P698

Q37172762-BEEADD0C-036B-4667-86CD-BC336F17BCC4

P932

Q37172762-93CE6B51-91BC-4D5B-B6C2-ABD0E28B88D5

P356

P1433

Neuropsychopharmacology

P1476

GSK-3 inhibition potentiates t ...... subthreshold doses of ketamine

@en

P2093

Ashley E Lepack

http://www.w3.org/2001/XMLSchema#string

George K Aghajanian

http://www.w3.org/2001/XMLSchema#string

Jason M Dwyer

http://www.w3.org/2001/XMLSchema#string

Manabu Fuchikami

http://www.w3.org/2001/XMLSchema#string

Ronald S Duman

http://www.w3.org/2001/XMLSchema#string

Rong-Jian Liu

http://www.w3.org/2001/XMLSchema#string

P2860

Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial

A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression

mTOR: from growth signal integration to cancer, diabetes and ageing

mTOR signaling: at the crossroads of plasticity, memory and disease

Stress blunts serotonin- and hypocretin-evoked EPSCs in prefrontal cortex: role of corticosterone-mediated apical dendritic atrophy

New approaches to antidepressant drug discovery: beyond monoamines

Long-lasting antidepressant action of ketamine, but not glycogen synthase kinase-3 inhibitor SB216763, in the chronic mild stress model of mice

Decreased expression of synapse-related genes and loss of synapses in major depressive disorder

Antidepressant effects of ketamine in depressed patients

A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression

P2888

P304

2268-2277

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NPP.2013.128

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

38

http://www.w3.org/2001/XMLSchema#string

P577

2013-05-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236915451

http://www.w3.org/2001/XMLSchema#string

P698

23680942

http://www.w3.org/2001/XMLSchema#string

P932

3773678

http://www.w3.org/2001/XMLSchema#string